All News


All series


All All News

The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.

Too often, the news, internet and social media focus on the sad stories. As survivors, it is up to us to focus on those stories that are positive and how survivors living their lives. I call it the living stories.

Patients with cancer are often asked when they’ll be done with chemotherapy or treatment. Those of us with blood cancers and bone marrow type of cancers such as aplastic anemia, myelodysplastic syndrome, lymphoma and leukemia, along with a host of other cancers sadly have to say, “never.”

Losing my hair, eyebrows and eyelashes didn't change who I was. It didn't change they people who loved me. Thanks to bright colors and make up, people told me all the time that I looked great.